A Phase I, Multiple Ascending Dose Study of BMS-663513, an Agonistic Anti-CD137 Monoclonal Antibody, Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies.

Trial Profile

A Phase I, Multiple Ascending Dose Study of BMS-663513, an Agonistic Anti-CD137 Monoclonal Antibody, Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2009

At a glance

  • Drugs Carboplatin; Paclitaxel; Urelumab
  • Indications Ovarian cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 09 Sep 2009 Planned end date changed from 1 Jul 2009 to 1 Mar 2009 as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top